NFX
vs
F
FTSE All Share Index
NFX
Over the past 12 months, NFX has significantly outperformed FTSE All Share Index, delivering a return of +162% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
NFX vs FTSE All Share Index
Performance Gap
NFX vs FTSE All Share Index
Performance By Year
NFX vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nuformix PLC
Glance View
Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. The company is headquartered in Cambridge, Cambridgeshire and currently employs 3 full-time employees. The company went IPO on 2015-12-17. The firm focuses on medical needs in fibrosis and oncology using drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting). NXP002, is its pre-clinical lead asset and used for inhaled treatment for idiopathic pulmonary fibrosis (IPF). NXP004, is an oncology drug that is used for the treatment of several cancers. The firm's subsidiary is Nuformix Technologies Limited.
